Jonas Båtelson of CuraCell has been featured in Citeline’s In Vivo, offering a sharp analysis of why platform‑driven models are becoming essential to the future of cell therapy. In his commentary, Båtelson argues that the sector’s next wave of winners will be those able to industrialise innovation by building scalable, modular platforms that reduce cost, accelerate development, and enable a broader pipeline of therapies.

His perspective positions CuraCell at the forefront of the industry conversation, highlighting the company’s strategic focus on technologies that can unlock true commercial viability for advanced cell‑based treatments.

Read the full article here.